Meritain Health policies, page 11

Search Meritain Health's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

5,481 public policies Substrate tracks for Meritain Health, by title.

Meritain Health policies
PolicyDetailsCodesSource
[Dental] 007 - Soft Tissue Graft Procedures007 · Commercial8Original policy ↗
[Dental] 008 - Full Mouth Debridement To Enable Comprehensive Evaluation and Diagnosis008 · Commercial1Original policy ↗
[Dental] 009 - Immediate Surgical Placement of Implant Body with Soft Tissue Grafting, Osseous Grafting and Guided Tissue Regeneration009 · Commercial15Original policy ↗
[Dental] 011 - Frenulectomy (Frenectomy, Frenotomy) or Frenuloplasty011 · Commercial11Original policy ↗
[Dental] 013 - Bone Replacement Grafts for Periodontal Surgical Procedures013 · Commercial2Original policy ↗
[Dental] 015 - Criteria for the Removal of Impacted Teeth015 · Commercial—Original policy ↗
[Dental] 018 - Obstructive Sleep Apnea018 · Commercial—Original policy ↗
[Dental] 019 - Temporomandibular Joint Syndrome (TMJ) and Temporomandibular Disorders (TMD)019 · Commercial—Original policy ↗
[Dental] 024 - Speech Generating Devices024 · Commercial—Original policy ↗
[Dental] 025 - Distraction Osteogenesis for Craniofacial Skeletal Deformities025 · Commercial—Original policy ↗
[Dental] 026 - Facial Prostheses, External026 · Commercial—Original policy ↗
[Dental] 027 - Intraoral Appliances for Headaches027 · Commercial—Original policy ↗
[Dental] 028 - Caries Detection Techniques028 · Commercial10Original policy ↗
[Dental] 029 - Occlusal Adjustment029 · Commercial2Original policy ↗
[Dental] 031 - Odontogenic Cysts031 · Commercial3Original policy ↗
[Dental] 033 - Space Maintenance in Primary Dentition - Loss of Primary Incisors033 · Commercial13Original policy ↗
[Dental] 034 - Temporary Anchorage Devices in Orthodontics034 · Commercial8Original policy ↗
[Dental] 036 - Treatment of Peri-implantitis036 · Commercial10Original policy ↗
[Dental] 037 - Bone and Tendon Graft Substitutes and Adjuncts037 · Commercial1Original policy ↗
[Dental] 038 - Resin Infiltration of Incipient Smooth Surface Lesions038 · Commercial1Original policy ↗
[Dental] 039 - Medically Necessary Orthodontia related to the Pediatric Dental Essential Benefit in the Affordable Care Act (ACA)039 · Commercial9Original policy ↗
[Dental] 040 - InitialPeriodontal Therapy Reevaluation040 · Commercial5Original policy ↗
[Dental] 041 - Scaling and Root Planing041 · Commercial4Original policy ↗
[Dental] 042 - Scaling in Presence of Generalized Moderate or Severe Gingival Inflammation042 · Commercial4Original policy ↗
[Dental] 043 - Core buildup043 · Commercial8Original policy ↗
[Dental] 044 - Diagnostic tools and/or devices044 · Commercial2Original policy ↗
[Dental] 046 - Temporomandibular Joint Dysfunction – Non-invasive Physical Therapies046 · Commercial1Original policy ↗
[Dental] 047 - Infiltration of Sustained Release Therapeutic Drug047 · Commercial6Original policy ↗
[Dental] 049 - Prefabricated porcelain/ceramic crown – permanent tooth049 · Commercial1Original policy ↗
[Pharmacy] 5-Alpha Reductase Inhibitors Non-TGC PA with Limit Policy 176-C 05-2022 - Specialty Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan176-C · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Limit 2-H 07-2022 - Specialty Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan2-H · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Limit 2-H P06-2024 v2 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug PlanP06-2024 v2 · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Limit 2-H P06-2024 v2 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug PlanP06-2024 v2 · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Limit 2-H P06-2025 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug PlanP06-2025 · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Limit Policy 2-H 06-2023 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan2-H · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Limit Policy 2-H 06-2023 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan2-H · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Limit Policy 2-H 07-2022 v2 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan2-H 07-2022 v2 · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Post Limit PA 1-J, 903-J P06-2024 v2 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan1-J, 903-J P06-2024 v2 · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Post Limit PA 1-J, 903-J P06-2024_R - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug PlanP06-2024_R · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Post Limit PA 1-J, 903-J P06-2024_R - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug PlanP06-2024_R · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Post Limit PA 1-J, 903-J P06-2025 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug PlanP06-2025 · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Post Limit PA Policy 1-J UDR 07-2022 v2 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan1-J UDR 07-2022 v2 · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Post Limit PA Policy 1-J UDR 07-2022 v2 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan1-J UDR 07-2022 v2 · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Post Limit PA Policy 1-J, 903-J 07-2022 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan1-J, 903-J · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Post Limit PA Policy 1-J, 903-J UDR 06-2023 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan1-J, 903-J · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist Post Limit PA Policy 903-J UDR 07-2022 v2 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan903-J · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist ST, Post PA (Aetna FI ACF, Aetna FI ACFC Only) 2936-D P06-2024_R - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan2936-D · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist ST, Post PA (Aetna FI ACF, Aetna FI ACFC Only) 2936-D P06-2024_R - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan2936-D · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist ST, Post PA (Aetna FI ACF, Aetna FI ACFC Only) 2936-D P06-2024_R - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan2936-D · Commercial—Original policy ↗
[Pharmacy] 5-HT1 Agonist ST, Post PA (Aetna FI ACF, Aetna FI ACFC Only) Policy 2936-D 07-2022 - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan2936-D · Commercial—Original policy ↗

Back to Meritain Health

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.